Company intelligence / Profile preview

Maxigen Biotech

Guishan District, Taoyuan City, Taiwanmbi-bio.com ↗

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Maxigen Biotech has commercialized a range of CE/FDA/NMPA-certified collagen and hyaluronic acid medical devices for orthopedics, ophthalmology, dental surgery, wound care, and aesthetics. Clinical trials include real-world effectiveness studies of intra-articular hyaluronic acid injections for knee osteoarthritis[8]. The company is recognized as an innovator in tissue regenerative materials with global sales presence[1][2][3][4][5].

Therapeutic areas: DermatologyOphthalmologyRheumatologyOther
Modalities: Collagen-based biomaterialsHyaluronic acid-based medical devicesSynthetic bone graftsRegenerative matrix (biologic)
Industry: Therapeutic Medical Devices

Partnerships

TCI Bio（major shareholder）NuVasive Inc.（shareholder; Nasdaq-listed US medtech company）OEM/ODM partnerships globally

Beyond the preview

Go deeper on Maxigen Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Maxigen Biotech.